PUBLISHER: Grand View Research | PRODUCT CODE: 1363310
PUBLISHER: Grand View Research | PRODUCT CODE: 1363310
Indian Clinical Trials Market Size, Share & Trends Analysis Report, By Phase (Phase I, Phase II, Phase III, Phase IV), By Study Design (Interventional Trials, Observational Trials), By Indication, By Region, And Segment Forecasts, 2023 - 2030
Indian Clinical Trials Market Growth & Trends:
The Indian clinical trials market size is expected to reach USD 3.87 billion by 2030, registering a CAGR of 8.3% from 2023 to 2030, according to a new report by Grand View Research, Inc.. The globalization of clinical trials, growing disease variation and prevalence in the country, adoption of new technology in clinical research, and increasing R&D promoting outsourcing are the key factors driving the market.
India is populated with 1.3 billion individuals with varying genetic backgrounds and a large treatment-naive patient pool for the development of therapeutics on a range of disease conditions. Furthermore, the economic, environmental, and ecological variations in the 28 states and 8 union territories present the most diverse disease profile. Apart from this, the cost of carrying out clinical trials in India is nearly 40-70% less when compared to that in Europe or the U.S. Thus, the cost efficiency, along with skill sets and ease of doing business, is anticipated to fuel the market growth.
The increasing R&D investments by pharmaceutical and biopharmaceutical companies have led to increased demand for contract research organizations and outsourcing of trials in order to curb the cost. Furthermore, outsourcing enables the drug companies to focus on their core competencies and aids in improving their productivity, thus facilitating the outsourcing of trials in India. The COVID-19 pandemic has improved the market in the country. Several companies globally are conducting clinical trials for COVID-19 vaccines in India. Moreover, government initiatives promoting clinical trials for COVID-19 therapeutics in the country have promoted market growth.
Indian Clinical Trials Market Report Highlights:
- By phase, the phase I segment is projected to register the fastest growth rate of 10.0% over the forecast period. This can be attributed to the increasing R&D spending by pharmaceutical and biopharmaceutical companies
- The interventional trials study design segment held the largest revenue share of over 40.8% in 2022 owing to the greater accuracy offered by them as compared to observational study design
- The oncology indication segment held the largest revenue share of over 24.9% in 2022 due to the increasing prevalence of the disease condition and the consequent rise in demand for innovative therapies for cancer
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.1.1. Phase
- 1.1.2. Study design
- 1.1.3. Indication
- 1.1.4. Estimates and forecast timeline
- 1.2. Research Methodology
- 1.3. Information Procurement
- 1.3.1. Purchased database
- 1.3.2. GVR's internal database
- 1.3.3. Secondary sources
- 1.3.4. Primary research
- 1.3.5. Details of primary research
- 1.4. Information or Data Analysis
- 1.5. Market Formulation & Validation
- 1.6. Model Details
- 1.7. List of Secondary Sources
- 1.8. List of Primary Sources
- 1.9. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Phase outlook
- 2.2.2. Study design outlook
- 2.2.3. Indication outlook
- 2.3. Competitive Insights
Chapter 3. Indian Clinical Trials Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Penetration & Growth Prospect Mapping
- 3.3. Market Dynamics
- 3.3.1. Market driver analysis
- 3.3.2. Market restraint analysis
- 3.4. Indian Clinical Trials Market Analysis Tools
- 3.4.1. Industry Analysis - Porter's
- 3.4.1.1. Supplier power
- 3.4.1.2. Buyer power
- 3.4.1.3. Substitution threat
- 3.4.1.4. Threat of new entrant
- 3.4.1.5. Competitive rivalry
- 3.4.2. PESTEL Analysis
- 3.4.2.1. Political landscape
- 3.4.2.2. Technological landscape
- 3.4.2.3. Economic landscape
- 3.4.1. Industry Analysis - Porter's
Chapter 4. Indian Clinical Trials: Phase Estimates & Trend Analysis
- 4.1. Indian Clinical Trials Market: Key Takeaways
- 4.2. Indian Clinical Trials Market: Movement & Market Share Analysis, 2022 & 2030
- 4.3. Phase I
- 4.3.1. Phase I market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.4. Phase ll
- 4.4.1. Phase ll market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.5. Phase lll
- 4.5.1. Phase lll market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.6. Phase lV
- 4.6.1. Phase lV market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Indian Clinical Trials: Study Design Estimates & Trend Analysis
- 5.1. Indian Clinical Trials Market: Key Takeaways
- 5.2. Indian Clinical Trials Market: Movement & Market Share Analysis, 2022 & 2030
- 5.3. Interventional Trials
- 5.3.1. Interventional trials market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.4. Observational Trials
- 5.4.1. Observational trials market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.5. Expanded Access Trials
- 5.5.1. Expanded access trials market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. Indian Clinical Trials: Indication Estimates & Trend Analysis
- 6.1. Indian Clinical Trials Market: Key Takeaways
- 6.2. Indian Clinical Trials Market: Movement & Market Share Analysis, 2022 & 2030
- 6.3. Autoimmune/Inflammation
- 6.3.1. Autoimmune/inflammation market estimates and forecasts, 2018 to 2030 (USD Million)
- 6.3.2. Rheumatoid arthritis
- 6.3.2.1. Rheumatoid arthritis market estimates and forecasts, 2018 to 2030 (USD Million)
- 6.3.3. Multiple sclerosis
- 6.3.3.1. Multiple sclerosis market estimates and forecasts, 2018 to 2030 (USD Million)
- 6.3.4. Osteoarthritis
- 6.3.4.1. Osteoarthritis market estimates and forecasts, 2018 to 2030 (USD Million)
- 6.3.5. Irritable bowel syndrome (IBS)
- 6.3.5.1. Irritable bowel syndrome (IBS) market estimates and forecasts, 2018 to 2030 (USD Million)
- 6.3.6. Others
- 6.3.6.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
- 6.4. Pain Management
- 6.4.1. Pain management market estimates and forecasts, 2018 to 2030 (USD Million)
- 6.4.2. Chronic pain
- 6.4.2.1. Chronic pain market estimates and forecasts, 2018 to 2030 (USD Million)
- 6.4.3. Acute pain
- 6.4.3.1. Acute pain market estimates and forecasts, 2018 to 2030 (USD Million)
- 6.5. Oncology
- 6.5.1. Oncology market estimates and forecasts, 2018 to 2030 (USD Million)
- 6.5.2. Blood cancer
- 6.5.2.1. Blood cancer market estimates and forecasts, 2018 to 2030 (USD Million)
- 6.5.3. Solid tumors
- 6.5.3.1. Solid tumors market estimates and forecasts, 2018 to 2030 (USD Million)
- 6.5.4. Others
- 6.5.4.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
- 6.6. CNS Condition
- 6.6.1. CNS condition market estimates and forecasts, 2018 to 2030 (USD Million)
- 6.6.2. Epilepsy
- 6.6.2.1. Epilepsy market estimates and forecasts, 2018 to 2030 (USD Million)
- 6.6.3. Parkinson's disease
- 6.6.3.1. Parkinson's disease market estimates and forecasts, 2018 to 2030 (USD Million)
- 6.6.4. Huntington's disease
- 6.6.4.1. Huntington's disease market estimates and forecasts, 2018 to 2030 (USD Million)
- 6.6.5. Stroke
- 6.6.5.1. Stroke market estimates and forecasts, 2018 to 2030 (USD Million)
- 6.6.6. Traumatic brain injury
- 6.6.6.1. Traumatic brain injury market estimates and forecasts, 2018 to 2030 (USD Million)
- 6.6.7. Amyotrophic lateral sclerosis
- 6.6.7.1. Amyotrophic lateral sclerosis market estimates and forecasts, 2018 to 2030 (USD Million)
- 6.6.8. Muscle regeneration
- 6.6.8.1. Muscle regeneration market estimates and forecasts, 2018 to 2030 (USD Million)
- 6.6.9. Others
- 6.6.9.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
- 6.7. Diabetes
- 6.7.1. Diabetes market estimates and forecasts, 2018 to 2030 (USD Million)
- 6.8. Obesity
- 6.8.1. Obesity market estimates and forecasts, 2018 to 2030 (USD Million)
- 6.9. Cardiovascular
- 6.9.1. Cardiovascular market estimates and forecasts, 2018 to 2030 (USD Million)
- 6.10. Others
- 6.10.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 7. Competitive Landscape
- 7.1. Recent Developments & Impact Analysis, By Key Market Participants
- 7.2. Market Participant Categorization
- 7.2.1. IQVIA holdings Inc. (QUintilesIMS)
- 7.2.1.1. Company overview
- 7.2.1.2. Financial performance
- 7.2.1.3. Product benchmarking
- 7.2.1.4. Strategic initiatives
- 7.2.2. Paraxel International Corporation
- 7.2.2.1. Company overview
- 7.2.2.2. Financial performance
- 7.2.2.3. Product benchmarking
- 7.2.2.4. Strategic initiatives
- 7.2.3. Pharmaceutical Product Development, LLC
- 7.2.3.1. Company overview
- 7.2.3.2. Financial performance
- 7.2.3.3. Product benchmarking
- 7.2.3.4. Strategic initiatives
- 7.2.4. Charles River Laboratory
- 7.2.4.1. Company overview
- 7.2.4.2. Financial performance
- 7.2.4.3. Product benchmarking
- 7.2.4.4. Strategic initiatives
- 7.2.5. ICON plc
- 7.2.5.1. Company overview
- 7.2.5.2. Financial performance
- 7.2.5.3. Product benchmarking
- 7.2.5.4. Strategic initiatives
- 7.2.6. PRA Health Sciences, INC.
- 7.2.6.1. Company overview
- 7.2.6.2. Financial performance
- 7.2.6.3. Product benchmarking
- 7.2.6.4. Strategic initiatives
- 7.2.7. Chiltern International Ltd. (Covance Inc.)
- 7.2.7.1. Company overview
- 7.2.7.2. Financial performance
- 7.2.7.3. Product benchmarking
- 7.2.7.4. Strategic initiatives
- 7.2.8. Syneos Health Inc. (inc research)
- 7.2.8.1. Company overview
- 7.2.8.2. Financial performance
- 7.2.8.3. Product benchmarking
- 7.2.8.4. Strategic initiatives
- 7.2.9. SGS SA
- 7.2.9.1. Company overview
- 7.2.9.2. Financial performance
- 7.2.9.3. Product benchmarking
- 7.2.9.4. Strategic initiatives
- 7.2.10. Syngene International Limited
- 7.2.10.1. Company overview
- 7.2.10.2. Financial performance
- 7.2.10.3. Product benchmarking
- 7.2.10.4. Strategic initiatives
- 7.2.11. Aurigene Discovery Technologies Limited
- 7.2.11.1. Company overview
- 7.2.11.2. Financial performance
- 7.2.11.3. Product benchmarking
- 7.2.11.4. Strategic initiatives
- 7.2.12. Aragen Life Sciences
- 7.2.12.1. Company overview
- 7.2.12.2. Financial performance
- 7.2.12.3. Product benchmarking
- 7.2.12.4. Strategic initiatives
- 7.2.13. Abiogenesis Clinpharm Pvt Ltd
- 7.2.13.1. Accelsiors Company overview
- 7.2.13.2. Financial performance
- 7.2.13.3. Product benchmarking
- 7.2.13.4. Strategic initiatives
- 7.2.14. Accelsiors
- 7.2.14.1. Company overview
- 7.2.14.2. Financial performance
- 7.2.14.3. Product benchmarking
- 7.2.14.4. Strategic initiatives
- 7.2.15. Accutest Global
- 7.2.15.1. Company overview
- 7.2.15.2. Financial performance
- 7.2.15.3. Product benchmarking
- 7.2.15.4. Strategic initiatives
- 7.2.16. Clario
- 7.2.16.1. Company overview
- 7.2.16.2. Financial performance
- 7.2.16.3. Product benchmarking
- 7.2.16.4. Strategic initiatives
- 7.2.17. Cliantha Research
- 7.2.17.1. Company overview
- 7.2.17.2. Financial performance
- 7.2.17.3. Product benchmarking
- 7.2.17.4. Strategic initiatives
- 7.2.18. Cliniminds
- 7.2.18.1. Company overview
- 7.2.18.2. Financial performance
- 7.2.18.3. Product benchmarking
- 7.2.18.4. Strategic initiatives
- 7.2.19. CliniRx
- 7.2.19.1. Company overview
- 7.2.19.2. Financial performance
- 7.2.19.3. Product benchmarking
- 7.2.19.4. Strategic initiatives
- 7.2.20. JSS Medical Research
- 7.2.20.1. Company overview
- 7.2.20.2. Financial performance
- 7.2.20.3. Product benchmarking
- 7.2.20.4. Strategic initiatives
- 7.2.1. IQVIA holdings Inc. (QUintilesIMS)
List of Tables
- Table 1 List of Abbreviations
- Table 2 India clinical trials market, by phase, 2018 - 2030 (USD Million)
- Table 3 India clinical trials market, by study design, 2018 - 2030 (USD Million)
- Table 4 India clinical trials market, by indication, 2018 - 2030 (USD Million)
List of Figure
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Indian clinical trials: Market outlook
Fig. 9 Indian clinical trials: Competitive insights
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook
Fig. 12 Penetration and growth prospect mapping
Fig. 13 Industry value chain analysis
Fig. 14 Indian clinical trials market driver impact
Fig. 15 Indian clinical trials market restraint impact
Fig. 16 Indian clinical trials market strategic initiatives analysis
Fig. 17 Indian clinical trials market: Phase movement analysis
Fig. 18 Indian clinical trials market: Phase outlook and key takeaways
Fig. 19 Phase I market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 20 Phase II market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 21 Phase III market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 22 Phase IV market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 23 Indian clinical trials market: Study design movement analysis
Fig. 24 Indian clinical trials market: Study design outlook and key takeaways
Fig. 25 Interventional trials market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 26 Observational trials market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 27 Expanded access trials market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 28 Indian clinical trials market: Indication movement analysis
Fig. 29 Indian clinical trials market: Indication outlook and key takeaways
Fig. 30 Autoimmune/inflammation market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 31 Rheumatoid arthritis market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 32 Multiple sclerosis market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 33 Osteoarthritis market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 34 Irritable bowel syndrome (IBS) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 35 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 36 Pain management market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 37 Chronic pain market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 38 Acute pain market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 39 Oncology market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 40 Blood cancer market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 41 Solid tumors market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 42 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 43 CNS Conditions market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 44 Epilepsy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 45 Parkinson's Disease market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 46 Huntington's Disease market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 47 Stroke market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 48 Traumatic brain injury (TBI) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 49 Amyotrophic lateral sclerosis (ALS) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 50 Muscle regeneration market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 51 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 52 Diabetes market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 53 Obesity market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 54 Cardiovascular market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 55 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 56 India market estimates and forecasts, 2018 - 2030 (USD Million)
